Dyne-2026-JPM.pdf

1、Advancing Clinically Validated Platform Toward Commercialization44THANNUAL J.P.MORGAN HEALTHCARE CONFERENCE|JANUARY 2026Forward-Looking Statements&Disclaimer2This presentation contains forward-looking statements that involve substantial risks and uncertainties.All statements,other than statements of

2、 historical fact,contained in this presentation,including statements regarding Dynes strategy,future operations,prospects and plans,objectives of management,the potential of the FORCE platform and its conjugates,the therapeutic potential of zeleciment basivarsen(z-basivarsen,also known as DYNE-101),

3、zeleciment rostudirsen(z-rostudirsen,also known as DYNE-251),DYNE-302 and DYNE-401,the anticipated timelines for reporting additional data from the ACHIEVE clinical trial,enrolling registrational cohorts and initiating additional clinical trials,expectations regarding the timing and outcome of inter

4、actions with global regulatory authorities and the availability of expedited approval pathways for z-basivarsen and z-rostudirsen,expectations regarding the timing of submitting applications for U.S.Accelerated Approval,plans to provide future updates on pipeline programs,expectations regarding the

5、commercialization of any of Dynes product candidates,and the sufficiency of Dynes cash resources for the period anticipated,constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.The words“anticipate,”“believe,”“continue,”“could,”“estimate,”“

6、expect,”“intend,”“may,”“might,”“objective,”“ongoing,”“plan,”“predict,”“project,”“potential,”“should,”“will”or“would,”or the negative of these terms,or other comparable terminology are intended to identify forward-looking statements,although not all forward-looking statements contain these identifyin